First Insight(R) And DrFirst(R) Launch A True "End-to-End" E-Prescribing Solution For The Ophthalmic Industry
First Insight Corporation, a leading practice management and electronic medical records (EMR) software company, and DrFirst, the leader in electronic prescribing and medication reconciliation, announced that First Insight is the first practice management and EMR software company focused exclusive
Protect Your Eyes And Attend Professional Fireworks Displays
This year for the 4th of July celebrations, the American Optometric Association (AOA) suggests that families and friends stay away from private firework use and instead enjoy professional displays to protect and preserve eyesight. Each year over the holiday, thousands of adults and children are seriously injured as a result of fireworks and pyrotechnic devices. Many burns and injuries affect eyesight, permanently damaging and in some cases blinding the victims.
Long-term results of primary TTT promising for treating choroidal melanoma
Long-term results of primary transpupillary thermal therapy to treat choroidal malignant melanoma have shown that the therapy is useful, but the study authors said that it is should be used in specific cases.
Inotek Commences Phase 1 Trial In Glaucoma With Selective Adenosine 1 (A1) Agonist
Inotek Pharmaceuticals Corporation announced that it has begun enrollment in a Phase 1 clinical trial with the Company's selective Adenosine 1 agonist, INO-8875, for the treatment of glaucoma. In March, Inotek received approval from the U.S. Food and Drug Administration to advance INO-8875 into clinical trials. The initial study will evaluate the safety, tolerability, and the potential of INO-8875 to lower intraocular pressure (IOP) in glaucoma patients.
Newly Published Study Shows OPKO's SiRNA Bevasiranib Is Taken Up By Target Tissues In The Eye
OPKO Health, Inc. (Amex: OPK) announced that a study published in the peer-reviewed journal Molecular Vision demonstrates that bevasiranib, its siRNA (small interfering RNA) agent is distributed throughout the eye, including extensive uptake into the retina. In two tissue distribution and pharmacokinetic studies in rabbits, results showed that bevasiranib was present in the retina and in targeted retinal pigment epithelium (RPE) cells following intravitreal injection.
For twelve years, experts from different disciplines in the fields of microelectronics, neurophysics, information engineering, computer science, materials science and medicine have been working to develop a visual prosthetic device for patients who have lost their sight through diseases of the retina. In September 2007, their effort was rewarded.
Ophthalmic solution successfully treats bacterial conjunctivitis, is well-tolerated
Azithromycin 1% ophthalmic solution showed statistically significant results in treating bacterial conjunctivitis in both adults and children, a multicenter prospective study found.
